These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38999436)

  • 21. Natural history of metabolic dysfunction-associated steatotic liver disease.
    Lekakis V; Papatheodoridis GV
    Eur J Intern Med; 2024 Apr; 122():3-10. PubMed ID: 37940495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
    Burmeister Y; Weyer K; Dörre A; Seilheimer B
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
    Noureddin N; Copur-Dahi N; Loomba R
    Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting.
    Allen AM; Charlton M; Cusi K; Harrison SA; Kowdley KV; Noureddin M; Shubrook JH
    Postgrad Med; 2024 Apr; 136(3):229-245. PubMed ID: 38465573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic dysfunction-associated steatotic liver disease: Navigating terminological evolution, diagnostic frontiers and therapeutic horizon-an editorial exploration.
    Boldys A; Buldak L
    World J Gastroenterol; 2024 May; 30(18):2387-2390. PubMed ID: 38764762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic-Dysfunction-Associated Steatohepatitis.
    Tincopa MA; Loomba R
    Semin Liver Dis; 2024 Jul; ():. PubMed ID: 38981691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
    Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
    JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pathophysiology of MASLD: an immunometabolic perspective.
    Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H
    Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update in lean metabolic dysfunction-associated steatotic liver disease.
    Sato-Espinoza K; Chotiprasidhi P; Huaman MR; Díaz-Ferrer J
    World J Hepatol; 2024 Mar; 16(3):452-464. PubMed ID: 38577539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etiology-Specific Effects of Impaired Functional Status on Liver Transplant Outcomes.
    Lee DU; Bhowmick K; Althwanay A; Sandlow S; Wiseman M; Lee KJ; Fan GH; Chou H; Chou H; Schuster K; Lee K; Lominadze Z
    Dig Dis Sci; 2024 Sep; 69(9):3513-3553. PubMed ID: 39014101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Wild-Type and High-risk PNPLA3 variants in a Human Biomimetic Liver Microphysiology System for Metabolic Dysfunction-associated Steatotic Liver Disease Precision Therapy.
    Xia M; Varmazyad M; Palacin IP; Gavlock DC; Debiasio R; LaRocca G; Reese C; Florentino R; Faccioli LAP; Brown JA; Vernetti LA; Schurdak ME; Stern AM; Gough A; Behari J; Soto-Gutierrez A; Taylor DL; Miedel M
    bioRxiv; 2024 May; ():. PubMed ID: 38712213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between Metabolic-Dysfunction-Associated Steatotic Liver Disease and Hepatic Cancer: Current Concepts and Future Challenges.
    Bader H; Yamin S; Alshahwan H; Farraj H; Maghnam J; Abu Omar Y
    J Clin Med; 2024 May; 13(11):. PubMed ID: 38892843
    [No Abstract]   [Full Text] [Related]  

  • 33. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring autoantibodies as predictors of severe fibrosis or cirrhosis in metabolic dysfunction associated with steatotic liver disease.
    Ragheb M; Grubert Van Iderstine M; Minuk G; Faisal N
    Can Liver J; 2024 May; 7(2):291-298. PubMed ID: 38746864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Backer S; Khanna D
    Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Elshaer A; Chascsa DMH; Lizaola-Mayo BC
    Life (Basel); 2024 Jul; 14(7):. PubMed ID: 39063598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gender Differences in Liver Steatosis and Fibrosis in Overweight and Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease before and after 8 Weeks of Very Low-Calorie Ketogenic Diet.
    Rinaldi R; De Nucci S; Donghia R; Donvito R; Cerabino N; Di Chito M; Penza A; Mongelli FP; Shahini E; Zappimbulso M; Pesole PL; Coletta S; Triggiani V; Cozzolongo R; Giannelli G; De Pergola G
    Nutrients; 2024 May; 16(10):. PubMed ID: 38794646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Nendouvhada LP; Sibuyi NRS; Fadaka AO; Meyer S; Madiehe AM; Meyer M; Gabuza KB
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.